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Background: Oncoviruses such as HPV, KSHV, and EBV have been reported in patients with HIV infection and AIDS.
How oncovirus-associated cancers rise in AIDS patients has not been fully established. The purpose of our study
was to identify the viral agents in vulvar cancer and to assess their contribution to pathogenesis.
Method: We retrospectively identified a total of 13 vulva tissue samples from HIV-1 positive and 9 vulvar samples
from HIV-1 negative patients from the Botswana National Health Laboratory in Gaborone, Botswana, a Southern
African country with a high incidence of HIV. We utilized PCR and IHC to identify HPV, EBV, KSHV, and JC virus in
FFPE preserved tissue samples.
Results: Using the GP5+/GP6+ primer set we detected several HPV types in tissue samples. EBV was detected in all
of the positive cases (100%) and in most of the negative cases (89%). KSHV was detected in 39% of the HIV-1
positive samples and in 11% of the negative samples, and no JC virus was detected in any of the samples.
Using IHC we demonstrated that LANA was expressed in 61% of the positive samples and in 44% of the negative
samples. The ubiquitous EBV was more consistently expressed in negative cases (100%) than in positive cases (69%).
Interestingly, the HPV-16 E6 transcript was detected in 56% of the negative samples compared to 31% of the
positive samples. However, the cell cycle protein P21 used as a surrogate marker for HPV was detected in 77%
of the positive samples and in 44% of the negative samples, while VEGF signals were similar in both positive
(92%) and negative samples (89%).
Conclusion: Our study, suggests that in Botswana, vulvar squamous cell carcinoma (VSCC) is associated with
oncogenic viruses present in the niche but the contribution and progression may be regulated by HPV and other
immunosuppressive infections that include HIV-1.
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There are two types of vulvar cancer. The first type that
develops from intraepithelial neoplasia caused by human
papillomavirus (HPV) infection, shows multifocality, and
is increasing in prevalence among young women and es-
pecially those with multiple co-infections including HIV
[1]. The second type, differentiated or simplex, is more
often seen in older women with p53 alterations and
likely develops from non-neoplastic epithelial disorders
as a result of chronic inflammation [1]. Basta et al., ob-
served strong correlation between patients younger than* Correspondence: simbirik@upstate.edu
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unless otherwise stated.45 years and HPV, cigarette smoking, having more than
two sexual partners, sexual initiation before age 19 years,
and low socioeconomic status [2]. In patients older than
45 years, there was correlation between vulvar intrae-
pithelial neoplasia (VIN) and non-neoplastic epithelial
disorders (VNED), residence in rural area, low economic
status, menopause before age 45, poor hygiene, endocrine
disorders, and low serum vitamin A levels. Pilotti et al. in
a study of patients with intraepithelial lesions reported a
strong correlation with the presence of HPV-16 DNA,
cigarette smoking, and herpes simplex cofactor [3]. Fur-
ther they reported that alteration of p53 by either inter-
action with viral oncoproteins or somatic mutations could
be crucial to the pathogenesis of vulva carcinomas, and
that p53 mutations are mainly associated with diseaseLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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and co-infection with HSV-2 and Chlamydia trachomatis
in vulvar intraepithelial neoplasia Kwasniewska et al. re-
ported that 73% were HPV-16 positive, 14.63% were HSV-
2 positive, and 14.63 Chlamydia trachomatis positive [5].
Hampl et al., in a German study of 224 patients with vulva
cancer identified between 1/1980 and 6/2007 noted a sig-
nificant shift in age with the initial period having 11% of
the women being under 50 years while the third period
had 41% of the women being less than 50 years, and that
two thirds of the women under 50 years were HPV posi-
tive [6]. They also noted that the tumor localization had
changed from labia to the area between the clitoris and ur-
ethra [6].
In sub-Saharan Africa there has been a paucity of vul-
var carcinoma studies and in the referenced studies the
rates of vulvar carcinomas are low and recently more as-
sociated with HIV infection [7-9]. Importantly, these stud-
ies have not investigated the link of vulvar cancer and
viral infections [10-12].Table 1 Patient characteristics
HIV negative
Age Bx site Diagnosis
1 32 Vulva SCC
2 79 Vulva SCC
3 35 Vulva SCC
4 52 Vulva SCC
5 79 Vulva SCC
6 69 Vulva SCC
7 62 Vulva SCC
8 42 Vulva SCC
9 70 Vulva SCC
HIV positive
1 39 Vulva SCC
2 37 Vulva SCC
3 41 Vulva SCC
4 49 Vulva SCC
5 35 Vulva SCC
6 32 Vulva SCC
7 35 Vulva SCC
8 41 Vulva SCC
9 35 Vulva SCC
10 40 Vulva SCC
11 29 Vulva SCC
12 48 Vulva SCC
13 32 Vulva SCC
The table shows age, patient diagnosis, the retroviral therapy status, and CD4 coun
carcinoma of the Vulva.
+= HIV positive; NO=HAART not administered and CD4 count not done.The aim of this study was to identify the oncogenic vi-
ruses in vulvar carcinoma tissues in HIV positive and
negative vulvar cancer patients from Botswana and to
assess the differential expression of cell cycle proteins
and growth factors that may be associated with trans-
formation of cells. Further, from strong evidence associ-
ating these proteins with G1 phase arrest dysregulation
and angiogenesis in some cancers we wanted to confirm
their expression in VSCC [13-15].
Materials and methods
We retrospectively identified a total of 13 vulva tissue sam-
ples from HIV-1 positive and 9 vulvar samples from HIV-1
negative patients from the Botswana National Laboratory
in Gaborone, Botswana (Table 1). Botswana Ministry
of Health, Princess Marina Hospital, and University
of Pennsylvania IRB approved this study (protocol #
812041). Princess Marina Hospital resident patholo-
gist and University of Pennsylvania dermatologist histo-























ts of each patient in the study. All patients were diagnosed with squamous cell
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http://www.infectagentscancer.com/content/9/1/28cell carcinoma (VSCC). Tissue samples were procured
from women above age eighteen with in situ or invasive
squamous cell vulvar cancer. Tissue samples were pre-
pared from the paraffin embedded samples by cutting
5 μm thick sections using different blades to limit cross
contamination, followed by de-paraffinization and extrac-
tion of the DNA. Total cellular DNA was extracted from
the vulvar tissues by digestion with proteinase K and
phenol-chloroform extraction as previously described
[16]. PCR analysis was performed as previously described
[17-21] with each virus specific primer including HPV
types using consensus primer GP5+/GP6+ that detects
more than 20 HPV types including, 11, 16, 18, 31, 33 and
45; EBV, KSHV, and JC virus. The PCR assay was per-
formed with primers HPV-L1 (150 bp); 5’TTTGTTAC
TGTGGTAGATACTAC-3’, 3’-CTTATACTAAATGTCAA
ATAAAAAG-5’; EBV-BamH1W (129 bp); 5’- CCAGACA
GCAGCCAATTGTC-3’, 3’-GGTAGAAGACCCCCTCTT
AC-5’; KSHV-ORF-73 (293 bp); 5’-CCATCTCTTGCATT
GCCAC-3’, 5’-AACTACGGTTGGCGAAGTCA-3’; and JC
VP2/VP3 (133 bp); 5’GAAGAACCCAAAACTATTTGTT
GAAA-3’, 5’-GCCTAACTGGAGACAATCTAGAATAAT
AGTC-3’. The PCR conditions were as follows: For HPV-
GpP5+/GP6+ 94°C for 5 minutes, 94°C for 30 seconds,
48°C for 30 seconds, and 72°C for 30 seconds, for 40 cy-
cles; elongation at 72°C for 5 minutes; and then incubation
at 4°C. For EBV-94°C for 5 minutes, 94°C for 30 seconds,
47°C for 30 seconds, and 72°C for 30 seconds, for 40 cy-
cles; elongation at 72°C for 5 minutes; and then incubation
at 4°C. For KSHV- 94°C for 5 minutes, 94°C for 30 sec-
onds, 52°C for 30 seconds, and 72°C for 30 seconds, for
40 cycles; elongation at 72°C for 5 minutes; and then incu-
bation at 4°C. The PCR products were run on 2.5% agar-
ose gel at 100 V for 1 hour.
In order to prevent PCR contamination we prepared
PCR reagents before each assay in a master mixture that
was then aliquoted. We prepared the master mixture,
extracted the DNA and added the template to the PCR
mixture in one area. The thermal cycling was performed
in a separate area. We took precautions against contam-
ination by using aerosol-barrier-protected pipette tips,
frequent changes of gloves, and repeated decontamin-
ation of surfaces with sodium hypochlorite.
Our sample extracts including positive controls and a
water specimen as an additional negative control to rule
out contamination of the reagents by aerosols, were also
subjected to PCR as described above. To support the
PCR findings for the presence of the oncogenic viruses,
HPV, EBV, and KSHV while concomitantly monitoring
changes associated with oncogenesis through expression
of known surrogate markers in tissues we performed im-
munohistochemistry on 5 μm thick paraffin- embedded
sections to detect virus specific antigens, cell cycle pro-
teins and vascular endothelial growth factor (VEGF) [9].We used commercial antibodies to HPV 16-E6 and E7
and HPV 18-E6 and E7 (DAKO Inc., Carpentaria, CA),
monoclonal antibody S12 for detection of EBV-LMP1,
monoclonal antibody derived from KSHV encoded LANA
[22], Cyclin D antibody (Santa Cruz, TX), p53 antibody
(Santa Cruz, TX), VEGF antibody (Abcam, MA), and p21
antibody (Abcam, MA).
Data analysis
The data for this study was collected in Excel and
imported into a statistical software program. Analysis
encompassed determination of proportions (MedCalc




In this study tissue blocks from 9 HIV negative patients
and 13 HIV positive patients were used (Table 1). We
performed PCR using different primers of HPV types,
EBV, KSHV, and JC virus. A larger percentage of high-
risk HPV types were detected in the tissues than low risk
HPV types. Using the GP5+/GP6+ primers we detected
HPV in 67% of the negative cases and 54% of the posi-
tive cases (OR = 0.57, CI = 0.32-1.02, P = 0.06) (Table 2).
HPV-18 was not detected in negative cases and in only 1
(8%) positive case. Though HPV-18 is usually detected
in fewer cases than HPV-16, the low number of positive
cases was surprising in this unique population. Equally
surprising was the detection of HPV-16 at similar levels
in the negative cases and positive cases 78% and 77% re-
spectively (OR = 0.94, CI = 0.48-1.83, P = 0.86) indicating
the ubiquity of HPV-16 in this population (Table 2).
More HPV-45 (56%) was detected in negative samples
than positive samples (39%) (OR = 0.50, CI = 0.28- 0.88,
P = 0.01) while HPV-33 was undetectable in negative
samples and in only one positive case (OR = 18.47, CI =
1.05-324, P = 0.04). Moreover HPV-31 was detected to a
greater degree in positive samples (85%) than negative
samples (67%) (OR =1.94, CI = 0.94-4.01, P =0.07). The
low risk HPV-11 was detected in fewer negative sam-
ples than positive samples (OR = 2.41, CI = 1.10-5.27,
P = 0.02) while HPV-6 was the same in the negative
samples (44%) and positive samples (46%) (OR = 1.08,
CI = 0.62-1.89, P = 0.78). EBV was detected in all the posi-
tive cases and in 89% of the negative cases (OR = 25.82,
CI = 1.50-444.6, P = 0.02). KSHV was detected in 39%
of the positive cases and 11% of the negative cases
(OR = 5.17, CI = 2.45-10.8, P < 0.01), and no JC virus was
detected in any patient sample (Table 2).
Immunohistochemistry
We performed IHC using a panel of antibodies that in-
cluded anti LANA in KSHV (Figure 1B), anti-LMP1 in
Table 2 PCR summary of HIV-1 negative and positive vulva cancer samples
Negative GP5+/6+ HPV-18 HPV-16 HPV-45 HPV-33 HPV-31 HPV-11 HPV-6 EBV KSHV P1/P2 KSHV F/R JC
1 + - - - - - - - + - - -
2 + - + + - + - + + - - -
3 - - + - - + - + + - - -
4 + - + + - + - - + - - -
5 + - + + - + - - + + - -
6 + - + + - + + - + - - -
7 + - + + - - - - + - - -
8 - - - - - - - + - - - -
9 - - + - - + - + + - - -
Total 67% 78% 56% 67% 11% 44% 89% 11%
Positive
1 + - + - - + - + + + + -
2 + - + - - + - + + + + -
3 + - + + + + - + + - + -
4 + - + - - + - + + - - -
5 + + + + - + - - + - + -
6 - - - - - - - + + + + -
7 - - - - - - + + + - - -
8 - - + - - + - - + - - -
9 - - + + - + + - + - - -
10 + - + - - + + - + + - -
11 - - - - - + - - + + - -
12 + - + + - + - - + - - -
13 - - + + - + - - + - - -
Total 54% 8% 77% 39% 8% 85% 23% 46% 100% 39% 39%
OR 0.57 18.47 0.94 0.50 18.47 1.94 2.41 1.08 25.82 5.17 129.09 NA
CI 0.32-1.02 1.05-324.5 0.48-1.83 0.28- 0.88 1.05- 324 0.94-4.01 1.10-5.27 0.62-1.89 1.50-444.6 2.45-10.8 7.7-2138.5 NA
P Value 0.06 0.04 0.86 0.01 0.04 0.07 0.02 0.78 0.02 <0.01 <0.01 NA
Oncogenic viruses identified in each VSCC patient as determined by PCR analysis. Most cases tested positive for HPV, EBV, KSHV, and HSV in HIV-1 positive and
negative samples. None was positive for JC virus.
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E7 (Figure 1D). We also used antibodies against the cell
cycle proteins P21 (Figure 1F), Cyclin D1 (Figure 1E),
and VEGF. We observed that LANA was expressed in a
larger percentage of positive HIV-1 samples (61%) com-
pared to the negative samples (44%) (OR = 1.99, CI =
1.13-3.49, P = 0.01) (Table 3). The ubiquitous EBV, noted
earlier in our previous paper [23] was highly expressed
in more negative cases (100%) compared to the HIV
positive cases (69%) (OR = 0.01, CI = 0.01-0.18, P =
0.001). Surprisingly, HPV-16 E6 was detected in more
negative samples (56%) than positive samples (31%)
(OR = 0.35, CI = 0.19-0.63, P = 0.004). HPV-16 E7 was
similar in both negative and positive samples (77%)
(OR = 1.0, CI = 0.51-1.93, P = 1.0). The P21 cell cycle
marker was detected in more positive samples (77%)than in negative samples (44%) (OR = 4.26, CI = 2.31-
7.84, P < 0.001). Cyclin D1 was expressed in more nega-
tive samples (88%) than positive samples (54%) (OR =
6.24, CI = 3.04-12.83, P < 0.001) while VEGF signals were
detected in 89% of negative samples and 92% of the
positive samples (OR = 1.42, CI = 0.54-3.6, P = 0.47)
(Table 3).Multiple HPV types detected in vulvar samples
GP5+/GP6+ and specific HPV primers were used for
our PCR amplification. GP5+/GP6+ primer can detect at
least 20 HPV types and has been used widely in clinical
assays [19,20,23]. In our experiments using these primers
we detected multiple HPV types in the VSCC tissues. The
results showed that high risk HPV-16, 18, 45, 31, and 33
Figure 1 Representative immunohistochemistry results of selected VSCC tissues. Panel A. shows brown staining positive cells for LMP1
using supernatant from the S12 hybridoma; panel B. shows brown staining positive cells using KSHV-LANA antibody; panel C. shows brown
staining positive cells using HPV-16-E6 antibody; panel D. shows brown staining positive cells using HPV-16 E7 antibody; panel E shows brown
staining using Cyclin D1 antibody; panel F. shows brown staining using p21Waf1/Cip1 antibody; panel G. shows negative staining without
antibody, and panel H shows negative sample control. Magnification at 40X.
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Table 3 Immunohistochemistry summary of HIV-1 negative and positive vulva cancer samples
Negative IHC-LANA LMP1 Cyc. D1 HPV16-E7 HPV16 E6 p21Waf1/Cip1 VEGF
1 - + + +++ + + -
2 - + + - + ++ +++
3 - + - - + - +
4 + + + + - + ++
5 + + ++ ++ - - ++
6 + + ++ ++ - - +++
7 - + + + + + +
8 + + + + + - +
9 - + + + - - +
Total 44% 100% 88% 77% 56% 44% 89%
Positive
1 - - + - - - -
2 + + + + - + +
3 - - - - - - +
4 - + + + - + +
5 - - - + - + ++
6 + + + ++ + ++ +
7 - - - - - - +
8 + + - + + + ++
9 + + + ++ + ++ ++
10 + + - + + + +
11 + + + +++ - +++ ++
12 + + + + - + ++
13 + + - + - + ++
Total 61% 69% 54% 77% 31% 77% 92%
OR 1.99 0.01 0.16 1.0 0.35 4.26 1.42
CI 1.13-3.49 0.01-0.18 0.07-0.32 0.51-1.93 0.19-0.63 2.31-7.84 0.54-3.6
P value 0.01 0.001 <0.01 1.00 0.004 <0.001 0.47
Oncogenic viruses identified in each VSCC patient as determined by Immunohistochemistry analysis. Most cases tested positive for KSHV, EBV, Cyclin D1, HPV16-E7,
HPV16-E6, p21, and VEGF.
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sample, a possible representation of the general popula-
tion prevalence (Table 2).
We detected high risk HPV in vulvar tissues by PCR and IHC
Utilizing PCR and IHC, high risk HPV-16 (OR = 1.05, 95%
CI = 0.54-2.05, P = 0.86); 18 (OR = 0.05, 5% CI = 0.03-9.09,
P = 0.046); 45 (OR = 2.3, 95% CI = 1.3-4.03, P = 0.003);
33 (OR = 1.05, 95% CI = 0.54-2.05, P = 0.86); and 31
(OR = 0.35, 95% CI = 0.17-0.71, P = 0.003) were de-
tected in the tissues of patients (Table 2). The level
of expression varied from patient to patient, however
it was observed that HPV-16, 31, and 45 were the
most frequently detected (Table 2). HPV-16 E6 and
E7 (Figures 1C,D) were detected in tissues by IHC.
Of interest was the detection of these viral types inboth the negative and positive cases almost to equiva-
lent levels suggesting similar exposure to these agents
in HIV positive and negative individuals.The ubiquitous agent EBV was detected at similar levels
in VSCCs and controls
EBV DNA was detected to almost equal levels in controls
and VSCC cases underscoring the ubiquity of the virus in
the population by PCR (OR = 0.03, 95% CI = 0.02-0.66, P =
0.02) (Table 2), and by IHC (OR = 91, 95% CI = 5.4-1513,
P = 0.001) (Table 3). The EBV viral genetic DNA was de-
tected in the tissues with other herpesviruses such as HPV
and KSHV. The similar levels of EBV in controls and cases,
and the possible association of EBV in initiation of VSCC
in HIV-1 infected cases warrants further investigation.
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compared to HIV negative VSCC control samples
KSHV, another oncogenic gammaherpesvirus that has
been associated with Kaposi’s sarcoma (KS) was identified
in positive cases more than in the negative controls by
PCR (OR = 0.193, 95% CI = 0.09-0.41, P < 0.001) (Table 2)
and by IHC (OR = 0.502, 95% CI = 0.28-0.88, P = 0.05)
(Table 3). Even though the findings are from a small sam-
ple, we noted similar results [23] with EBV, KSHV, and
HPV types equally represented in the cancerous tissues
suggesting further investigation on effects of oncogenic
viral interactions in initiation and maintenance of the
cancers.
Expression of cell cycle protein markers p21 and Cyclin
D1, as well as VEGF in vulvar samples as detected by IHC
We assayed for the cell cycle regulators p21 (Figure 1F)
and Cyclin D1 (Figure 1E), as well as VEGF in the tissue
samples using IHC. It was observed that p21 was signifi-
cantly higher in cases than in controls (OR = 0.23, CI =
0.21-0.43, p < 0.001) while Cyclin D1 was higher in the
negative controls (OR = 6.24, CI = 3.04-12.83, P < 0.001).
Interestingly, VEGF signals were similar in controls and in
VSCC cases (OR = 0.70, CI = 0.27-1.83, P = 0.47), respect-
ively (Table 3).
The PCR assay did not detect JC virus used as a negative
control for the samples
John Cunningham (JC) virus [18], which has been iden-
tified mostly in transplant patients, was also tested for
its presence in the samples. No JC virus signals were de-
tected in the controls nor the VSCC cases (Table 2).
CD4 counts and the cell cycle proteins
CD4 has been used as a marker of immunocompetence
in HIV infected patients, with higher CD4 counts indi-
cating better immune response in these patients to op-
portunistic infections and other pathogenic infections.
We assessed CD4 counts in relation to Cyclin D1 in the
VSCC cases and controls. We observed that in the HIV
positive VSCC cases the counts were 437.9 compared to
409.8 for the controls. For p21 signals the CD4 counts
were 410 for the HIV positive cases and 457 for the HIV
negative controls. For VEGF positive samples CD4 counts
were 430.1 for the HIV positive cases and 477 for the HIV
negative controls.
HAART therapy may contribute to the progression of
VSCC in HIV positive patients
The CD4 range for HIV positive individuals who were
not currently taking HAART average was 392 compared
to HIV positive cases taking HAART with an average of
457.5.There was a significant difference between cases who
were currently on HAART and those not taking HAART
(OR = 152.1, 95% CI = 9.1-2516.9, P = 0.0005). When com-
parison was made between HAART therapy and human
papilloma virus detection by PCR HPV-18 (OR = 0.0083,
95% CI = 0.0001-0.50, P = 0.02), HPV-33 (OR = 0.0083,
95% CI = 0.0001-0.50, P = 0.02), HPV-31 (OR = 121, 95%
CI = 2.02-7259.7, P = 0.02), HPV-6 (OR = 0.0083, 95%
CI = 0.0001-0.50, P = 0.02), as well as oncogenic her-
pesviruses EBV (OR = 121, 95% CI = 2.02-7259.7, P = 0.2),
and KSHV (OR = 0.0083, 95% CI = 0.0001-0.50, P = 0.02)
were significant while HPV-16 (OR = 16, 95% CI = 0.7215-
354.8, P = 0.07), HPV-45 (OR = 2.25, 95% CI = 0.17-28.3,
P = 0.53), and HPV-11 (OR = 0.06, 95% CI = 0.0028-1.39,
P = 0.08) were borderline significant (Table 2).
Age may have significant role in vulvar cancer in
Batswana women who are HIV positive
It was observed that the HIV positive cases with vulvar
cancer were typically younger with a median age of 38 years
while the HIV negative cases were generally older, me-
dian age 62 years (OR = 0.3757, 95% CI = 0.2122-0.66650,
P = 0.0008). This strongly suggests that in vulvar cancer,
HIV may be contributing to the initiation of the cancer in
younger females through pathways that have not been
fully delineated (Table 1).
ARV therapy and cell cycle protein expression
When we looked at the expression of cell cycle proteins
in cases on HAART compared to controls, we observed
no significant difference for Cyclin D1 (OR = 2.25, 95%
CI = 0.18-28.26, P = 0.53), whereas there were significant
differences for p21 (OR = 121, 95% CI = 2.02-7259.7, P =
0.02). For the growth factor VEGF (OR = 121, 95% CI =
2.02 = 7259.7, P = 0.02) also showed a significant differ-
ence for women who are on HAART compared to con-
trols (Table 3), though due to the small sample size it
may be important to evaluate this question with a larger
sample size.
Discussion
Studies indicate that a majority of keratinizing squamous
cell carcinomas usually found in older women are likely
to be non-HPV related [24,25]. Yet, due to other factors
such as cigarette smoking, multiple sex partners, and
other infections, women over 60 years can have HPV-
associated vulvar cancers [26]. In their study Madeleine
et al. observed high prevalence of HPV-16, and less
prevalence of HPV-18 and HPV-6 [26]. The authors also
indicated that HSV-2 may contribute to vulvar cancer
independently of HPV-16, through another yet to be
identified pathway. This may be routed in the stimula-
tion of the immune response as a result of the HSV in-
fection. Our study showed a similar trend, with more
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in both patients younger than 50 years and older who
were HIV-1 infected, with the younger HIV positive cases
having increased risk of having VSCC than older cases.
We observed a high incidence of EBV in both the HIV-1
negative and HIV-1 positive samples. Interestingly, as it
would be expected for opportunistic infections, more
KSHV was detected in the HIV-1 positive cases than HIV-
1 negative cases by both PCR and immunohistochemistry.
These findings were not entirely surprising since we ob-
served similar distribution of these viruses in Ocular sur-
face squamous neoplasia (OSSN) tissues from same
population in Botswana [23]. The implications of detec-
tion of oncogenic viruses from the small sample size calls
for more investigation. HPV was detected in positive sam-
ples as well as in controls. It is likely that in our cohort
contributing factors to VSCC initiation and maintenance
may include HIV-I and other infections that elicit inflam-
matory responses and also cause immunosuppression, be-
sides HPV.
The viral genes of HPV-16, E6 and E7 have been shown
to interfere with 2 pathways associated with cell cycle de-
regulations. E6 has been shown to interact with p53, caus-
ing p53 dysfunction and eventually disrupting cell cycle
arrest [27]. HPV-16 encoded E7 inactivates pRb leading to
overexpression of p16INK4A resulting in hyperproliferation
that can be detected by antibodies against Ki-67 nuclear
antigen present in all cell cycle stages of proliferating cells
except for the G0 phase that was expressed to a lower level
than HPV-16 E7 in our samples (Figure 1D) [27]. The
range in expression could be due to viral load of both
HIV-1 and HPV types and associated immunosuppres-
sion. The HIV-1 viral load depended on when HAART
therapy was initiated in each patient. In our study some of
the patients were on HAART, however, because of the
sample size it was difficult to decipher the effect of
HAART that could be generalized, though significant dif-
ferences were observed between those on HAART and
those not on HAART at the time of data collection.
Chaturvedi et al. [28], observed increased incidence, preva-
lence, and persistence of HPV infections and cofactors
such as cigarette smoking among HIV-1 infected patients
which led them to hypothesize that low CD4 count during
the pre-HAART era masked the association between im-
munosuppression and the risk of HPV related invasive
cancer that increased survival during the HAART era pro-
viding adequate time for progression of premalignant le-
sions to invasive cancers as suggested in our paper [23].
Chaturvedi et al. suggest that poor immune control
of premalignant lesions that may facilitate the devel-
opment of cancer and later progression to invasive cancer
is not affected by immunosuppression [28]. HAART has
been shown not to alter HPV persistence or rates of pro-
gression or regression of premalignant anogenital lesion[29,30]. Palesfky et al. suggest that the increase in anal
cancer in the HAART era may reflect the possibility that
in the pre-HAART era patients at highest risk of anal can-
cer would have died from other causes [29,30]. Since the
introduction of large scale HAART therapy in Botswana
took place in 2002 (WHO, 2006), most of the patients
who had these oncogenic neoplasias pre-HAART era died
without diagnosis or therapy.
Perturbation of cell cycle proteins was also considered a
factor in VSCC, thus we assayed for Cyclin D1 which is in
the p53 pathway, p21 which is downstream target of p53,
and VEGF whose contribution to vascularity is considered
essential for tumor progression [9,13-15,31,32]. Our ob-
servation of significant differences in p21, and Cyclin D1,
and no difference in VEGF necessitates a more robust and
broader study with a larger sample size. However, these
results do provide new evidence for a role of oncogenic vi-
ruses in development of VSCC.
Conclusion
Though our sample size is small we do suspect that simi-
lar immunological surveillance dysfunction and dysregula-
tion of specific pathways associated with viral oncogenesis
may be a factor in vulvar carcinoma pathogenesis. Add-
itional levels of investigation are needed in HIV-1 associ-
ated vulvar carcinoma to delineate the dysregulation these
viruses will initiate that leads to oncogenesis.
The findings of different oncogenic viruses and expres-
sion of cancer associated markers in tissues of women
with and without HIV in Botswana with VSCC warrants
further investigation with a larger sample size that may
lead to identification of molecular moieties for targeted
therapeutic and vaccine development. This Botswana co-
hort was unique in exposure to different environmental
and infectious agents that may have additional epigen-
etic effects on the outcome of VSCC [33].
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